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Context:  Weight  loss and  improved  blood  glucose  control  after bariatric  surgery  have  been  attributed  in
part to increased  ileal  nutrient  delivery  with  enhanced  release  of  glucagon-like  peptide  1 (GLP-1).  Non-
surgical  strategies  to  manage  obesity  are  required.  The  aim  of  the  current  study  was to assess  whether
encapsulated  glutamine,  targeted  to the  ileum,  could  increase  GLP-1  secretion,  improve  glucose  tolerance
or reduce  meal  size.
Methods: A  single-center,  randomised,  double  blind,  placebo-controlled,  cross-over  study  was  performed
in 24  healthy  volunteers  and  8  patients  with  type  2 diabetes.  Fasting  participants  received a single dose
of encapsulated  ileal-release  glutamine  (3.6  or 6.0  g) or placebo  per  visit  with  blood  sampling  at  baseline
and  for  4  h  thereafter.  Glucose  tolerance  and meal  size  were  studied  using  a 75  g oral  glucose  tolerance
test  and  ad  libitum  meal  respectively.
Results:  In healthy  volunteers,  ingestion  of 6.0  g  glutamine  was  associated  with  increased  GLP-1  concen-
trations  after  90  min  compared  with  placebo  (mean  10.6  pg/ml  vs 6.9 pg/ml,  p = 0.004),  increased  insulin
concentrations  after  90 min  (mean  70.9  vs  48.5,  p = 0.048),  and  increased  meal  size  at 120  min  (mean
542  g eaten  vs  481  g, p =  0.008).  Ingestion  of  6.0  g  glutamine  was  not  associated  with  signiﬁcant  differ-
ences  in GLP-1,  glucose  or  insulin  concentrations  after  a glucose  tolerance  test  in  healthy  or type  2 diabetic
participants.
Conclusions:  Single  oral  dosing  of  encapsulated  glutamine  did not  provoke  consistent  increases  in  GLP-1
and  insulin  secretion  and  was  not  associated  with  beneﬁcial  metabolic  effects  in healthy  volunteers  or
patients  with  type  2  diabetes.
©  2015  Published  by Elsevier  Inc.. Introduction
Over several decades, population levels of obesity, deﬁned as
ndividuals having a body mass index of 30 kg/m2 or more, have
ncreased in many countries worldwide. The World Health Organ-
sation now considers obesity to be one of the greatest public
ealth challenges to be faced in the 21st century [1]. Obesity and
elated conditions, such as type 2 diabetes mellitus (T2DM), are
Abbreviations: AUC, area under the curve; BMI, body mass index; CaSR, cal-
ium sensing receptor; CV, coefﬁcient of variation; DPP-IV, dipeptidyl peptidase-IV;
LP-1, glucagon-like peptide-1; GPCR, G-protein coupled receptor; HV, healthy vol-
nteer; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus; WHO,
orld Health Organisation.
∗ Corresponding author.
E-mail address: fmg23@cam.ac.uk (F. Gribble).
ttp://dx.doi.org/10.1016/j.peptides.2015.10.008
196-9781/© 2015 Published by Elsevier Inc.responsible for rising healthcare costs and a great burden of mor-
bidity and mortality. Both obesity and T2DM can be successfully
treated with bariatric surgery, although the precise mechanisms
responsible for these beneﬁcial effects remain poorly understood.
One possibility is that bariatric surgery improves diabetes and
aids weight loss by increasing nutrient delivery to the distal gut,
which stimulates release of the satiety-promoting incretin hor-
mone glucagon-like peptide 1 (GLP-1). Although GLP-1 mimetics
have been given pharmacologically in the treatment of T2DM and
obesity [2], an alternative would be to use agents which enhance
endogenous GLP-1 production to harness similar beneﬁts with
potentially fewer adverse effects.GLP-1 is produced in enteroendocrine L-cells in the mucosa of
the ileum and colon in response to nutrient exposure. Many differ-
ent proteins or amino acids have been found to stimulate GLP-1
release by interacting with the calcium-sensing receptor (CaSR)
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3,4], GPRC6A [5] or PEPT1 [4]. The amino acid glutamine is abun-
ant in the human diet and a particularly effective stimulant of
LP-1 release in vitro because it not only generates an electrical
ignal in L-cells but also elevates intracellular cAMP levels [6]. Oral
ngestion of glutamine in human volunteers was associated with
nhanced GLP-1 secretion and improved glucose tolerance, but a
ose of at least 15 g was required [7,8], possibly due to the low
tability of glutamine in gastric acid [9] and its absorption in the
pper GI tract resulting in relatively low levels reaching the ileal L-
ells. Encapsulation could circumvent this problem by facilitating
argeted release of nutrients into parts of the intestine where the
-cells are most abundant.
The aim of the current study was to assess the effect of encap-
ulated glutamine on GLP-1 concentrations, glucose tolerance and
eal size in healthy human volunteers and in individuals with
2DM.
. Methods
.1. Participant recruitment
Healthy male and female volunteers (18–65 years old; body
ass index (BMI) 18–35 kg/m2) were recruited using advertise-
ents in Addenbrooke’s Hospital and the University of Cambridge.
atients with T2DM (18–65 years old; BMI  of 18–40 kg/m2) were
dentiﬁed through primary care, outpatient clinics and using adver-
isements. Participants with anemia or other signiﬁcant active
iseases and those who  were pregnant or breastfeeding were
xcluded. Patients with T2DM who had taken insulin or injectable
LP-1 agonists were excluded from the study. Patients who were
aking metformin, sulphonylureas or dipeptidyl peptidase-IV (DPP-
V) inhibitors were asked to withhold these for 12, 24 and 72 h prior
o the test respectively.
Participants were provided with written information about the
tudy and gave written informed consent prior to participation.
he study was  given ethical approval by the Norfolk & Norwich
esearch Ethics Committee (Reference 12/EE/0389, 25/09/2012;
SRCTN 10757078).
Participants attended the clinical research facility in the morn-
ng following an overnight fast. The evening before each visit,
articipants had a standardized pasta meal (15% protein, 30% fat,
5% carbohydrate) designed to provide 33% of their daily calorie
equirement based upon an estimation of their metabolic rate and
ctivity levels [10].
.2. Capsule production
Capsule development and GMP  manufacture was performed
y Encap Drug Delivery Ltd. (Livingston, UK). Each capsule con-
ained 600 mg  of glutamine or 300 mg  microcrystalline cellulose
placebo). The capsules were manufactured with an enteric coat-
ng designed to promote capsule release 20 min  after exposure to
n alkaline environment.
.3. Study design
The capsules were tested in a series of blinded, controlled stud-
es in human volunteers. The primary endpoint was  the effect of the
apsules upon circulating concentrations of total GLP-1 in venous
lood. The secondary endpoints were safety, the effect of the cap-
ules upon glucose tolerance, meal size and subjective feelings of
unger and fullness..3.1. Fasting study
Initially, a single-blinded, non-randomised, placebo-controlled
ose-ranging study in four healthy volunteers was performed to 77 (2016) 38–46 39
ascertain the optimal dose for further evaluation and provide
preliminary safety data. The doses studied included placebo (10
capsules) and 0.6 g, 1.8 g. 3.6 g and 6.0 g glutamine supplemented
where necessary with placebo capsules to preserve participant
blinding. The remainder of the study used the two most promis-
ing doses, 3.6 and 6.0 g Glutamine in comparison to placebo in a
double-blind, controlled randomised design.
On each visit, venous blood was  taken at baseline and at intervals
following capsule ingestion for evaluation of GLP-1 concentrations.
Participants recorded adverse events in a symptom diary and com-
pleted questionnaires evaluating hunger, fullness and nausea. On
one visit, participants had a DXA scan. Ten healthy volunteers were
recruited for evaluation of the primary endpoint in the fasting com-
parison between placebo, 3.6 g Glutamine and 6.0 g Glutamine.
2.3.2. Glucose tolerance and meal size in healthy volunteers and
patients with T2DM
For evaluation of the effect on the capsules on glucose toler-
ance, nine healthy volunteers and eight patients with T2DM were
recruited. The study visits were similar to the fasting study except
that each participant had a 75 g oral glucose tolerance test (OGTT)
at 90 min  after capsule ingestion.
2.3.3. Meal size in healthy volunteers
For evaluation of the effect of the capsules on meal size, ten
healthy volunteers were recruited to attend the Clinical Research
Facility on three occasions for an ad libitum breakfast given 120 min
after capsule ingestion. The ad libitum meal consisted of muesli
with chopped fruit, nuts and milk in a homogenous mixture
designed to provide 15% protein, 30% fat and 55% carbohydrate.
A portion of 1.5 kg (2400 kcal) was  provided on each occasion and
participants were advised to eat until they felt full. The total amount
of food eaten was  measured using a universal eating monitor.
2.4. Questionnaire design
Hunger, fullness and nausea were assessed using a visual analog
scale which has been widely used in the medical literature [11].
2.5. Analytical methodology
For analysis of total GLP-1, samples were taken into EDTA
plasma tubes, placed on ice immediately after venesection and cen-
trifuged (3500 × g at 4 ◦C 10 min), aliquotted and frozen using dry
ice within 15 min  of venesection. Samples were stored at −80 ◦C
prior to batch analysis in duplicate of GLP-1 using the Mesoscale
Discovery Total GLP-1 kit, a sandwich immunoassay with elec-
trochemiluminescence detection which measures all endogenous
forms of GLP-1. This method has a range of 1.4–1000 pg/ml and
coefﬁcients of variation (CVs) of 5–7%.
For biochemistry testing, serum samples were allowed to clot
for 10 min  then centrifuged, separated and frozen within 30 min
of venesection and stored at −80 ◦C prior to analysis. Glucose, ala-
nine aminotransferase (ALT) and creatinine were measured in a
clinically-accredited laboratory at Addenbrooke’s hospital using a
Siemens’ Dimension analyzer with CVs of <2% within the reference
range. Thyroid stimulating hormone (TSH) was measured using a
Bayer ADVIA Centaur immunoassay system with CVs of <6% within
the reference range. HbA1c was  measured on fresh whole blood
using a Tosoh analyser with CVs of <5% within the reference range.
For measurement of insulin, samples were collected into lithium
heparin plasma tubes, placed on ice, centrifuged (3500 × g at 4 ◦C
10 min), aliquotted and frozen using dry ice within 15 min of vene-
section. Samples were stored at −80 ◦C prior to batch analysis
using the Diasorin Liaison, an immunoassay with chemilumines-
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ent detection. This method has a range of 20–3470 pmol/l and
ntra-assay CVs of <5%.
.6. Statistical analysis
Based on previous work [7], using a paired study design, it
as estimated that observing 8 subjects per comparison would
ave 90% power to detect an average difference of 6.0 pmol/l
19.8 pg/ml) of GLP-1. For each endpoint, 8–10 participants were
ecruited to allow for participant withdrawal. Plasma concentra-
ions of hormones and analytes in the text and ﬁgures are shown
s mean ± SEM.
As this was a cross-over study, each participant was  given
lacebo and active regimens in randomised order, using a pre-
repared protocol developed using a random number generation
ackage. Paired t tests were used to compare plasma levels of GLP-
, glucose and insulin and reported levels of hunger, fullness and
ausea according to a visual analog scale. Peak GLP-1 was  deﬁned as
he maximum concentration of GLP-1 for an individual on a single
tudy day. Peak GLP-1 was deﬁned as the maximum concentration
f GLP-1 for an individual on a single study day. Linear regression
as used to assess the differences between GLP-1, glucose and
nsulin concentrations between groups. STATA/SE 13.1 was  used
or analysis.
. Results
32 participants were recruited (24 healthy volunteers and 8
atients with T2DM). The baseline characteristics of the partic-
pants are listed in Table 1. Most healthy volunteers were aged
2–30 years old with a body mass index of 20–25 kg/m2 and around
5% body fat. As expected, the patients with T2DM were gener-
lly older and had a higher BMI, percentage fat mass and HbA1c
ompared to healthy volunteers. Most participants had normal
emoglobin, white cell count, ALT, TSH and creatinine at baseline.
.1. Dose ranging study: assessment of the dose-related effects of
lutamine capsules on circulating concentrations of total GLP-1 in
asting healthy volunteers
Four healthy volunteers were recruited to identify the opti-
al  dose for further study. The highest dose, 6.0 g Glutamine, was
ssociated with a signiﬁcant increase in peak GLP-1 concentra-
ion compared to placebo during (Fig. 1). Based on these results,
he doses chosen for further study were 3.6 g Glutamine and 6.0 g
lutamine in comparison to placebo.
.2. Assessment of the effect of glutamine capsules on circulating
oncentrations of total GLP-1 in healthy volunteers
Ten healthy volunteers were recruited to assess the effect of glu-
amine capsules on GLP-1 concentrations (Table 1; Fig. 2). Ingestion
f 6.0 g Glutamine was associated with an increase in peak GLP-1
mean ± SEM: 7.5 ± 4.1 pg/ml placebo vs 10.3 ± 2.6 pg/ml with 6.0 g
lutamine; p < 0.001). The area under the curve (AUC) for GLP-
 (from 0 to 240 min) was not signiﬁcantly different (1217 ± 154
s 1484 ± 241 pg × min/ml for placebo and 6.0 g Glutamine respec-
ively). There was no signiﬁcant difference in peak or AUC glucose,
nsulin, hunger, fullness or nausea between the regimens.
These results were different from those found during the
ose-ranging study (Fig. 1). Further examination of individual
articipants’ data showed one group (n = 7) with increased GLP-
 concentrations (responders) while other participants (n = 3)
howed no evidence of a GLP-1 response. In responders, the shape
f the GLP-1 curve was heterogeneous with marked differences 77 (2016) 38–46
between participants. There was also marked intra-individual vari-
ation in fasting GLP-1 concentrations in some participants between
each of the three visits which was not explained by altered diet or
exercise patterns within 24 h of the study visit.
3.3. Assessment of the effect of glutamine capsules on glucose
tolerance in healthy volunteers
Nine healthy volunteers were recruited to assess the effect
of glutamine capsules on glucose tolerance using an oral glu-
cose tolerance test (OGTT; Table 1; Fig. 3). After ingestion of 6.0 g
Glutamine, participants had signiﬁcantly higher concentrations of
insulin (mean ± SEM: 70.9 ± 13.4 vs 48.5 ± 7.8 pmol/l; p = 0.048)
and GLP-1 (10.6 ± 1.0 vs 6.9 ± 0.8 pg/ml; p = 0.004) at 90 min, i.e.
immediately prior to ingestion of the 75 g glucose load. No signiﬁ-
cant difference was seen in the area under the curve before or after
the OGTT for glucose, GLP-1, insulin, hunger, fullness or nausea.
3.4. The effect of encapsulated nutrients on concentrations of
GLP-1, glucose and insulin in patients with type 2 diabetes
Eight patients with T2DM were enrolled into the study and
attended for two visits for the assessment of hormone concentra-
tions and glucose tolerance using an OGTT given at 90 min  (Table 1;
Fig. 4) after placebo or 6.0 g Glutamine. There were no signiﬁcant
differences in peak concentrations of glucose, GLP-1 or insulin or in
reported levels of hunger, fullness or nausea. Area under the curve
before or after the OGTT for glucose, GLP-1 and insulin were similar
between active and placebo treatment regimens.
3.5. Assessment of the effect of glutamine capsules on meal size
Ten healthy volunteers were recruited to assess the effect of
glutamine capsules on meal size (Table 1). The group receiving
6.0 g Glutamine ate signiﬁcantly more food during the ad libitum
meal compared to the placebo group (mean 542 ± 65 g eaten vs
481 ± 71 g, p = 0.008; Fig. 5) and had reduced hunger scores post-
prandially (reduced area under the curve from 120 to 480 min,
p = 0.053; and 0 to 480 min, p = 0.031).
This ﬁnding was unexpected and contrary to the hypothesis.
Unfortunately, no blood samples were taken from participants dur-
ing the meal visit. However, participants had signiﬁcantly higher
hunger scores at 120 min  following ingestion of 6 g Glutamine,
before beginning the meal. On linear regression analysis, hunger at
120 min  was linearly related to the amount eaten when the model
was adjusted for gender (coefﬁcient 3.41, 95% conﬁdence interval
0.12–6.7, p = 0.042).
3.6. Assessment of the effect of glutamine capsules on hunger and
satiety
Overall, there was no signiﬁcant difference between peak or AUC
for hunger, fullness or nausea for these variables between the three
different regimens (Figs. 2–4) except during the meal study (Fig 5).
Hunger and fullness were linearly related and hunger scores tended
to be lower where nausea scores were high (Fig. S1).
4. Discussion
This study demonstrates that up to 6 g of encapsulated
glutamine is unable to provoke a physiologically or clinically sig-
niﬁcant increase in plasma total GLP-1 concentrations in fasting
healthy volunteers and is not associated with beneﬁcial effects
upon glucose tolerance or meal size. As evident by comparing the
results shown in Figs. 1 and 2, some individuals showed small
responses to capsule ingestion. However, the magnitude of these
C.L. Meek et al. / Peptides 77 (2016) 38–46 41
Table  1
Baseline characteristics of study participants—characteristics shown as median (range). HV: healthy volunteers; T2DM: patients with type 2 diabetes mellitus.
HV: assessment of GLP-1
concentrations
n = 10
HV: assessment of glucose
tolerance
n = 9
HV: assessment of meal
sizea
n = 10
T2DM: assessment of
glucose tolerance
n = 8
Gender 5 male, 5 female 4 male, 5 female 5 male, 5 female 4 male, 4 female
Age  (years at enrolment) 31.3 (9.7) 36.2 (10.5) 33.9 (10.2) 57.9 (10.7)
Body  Mass Index (kg/m2) 22.9 (3.5) 25.0 (3.9) 23.4 (4.1) 32.5 (5.6)
Waist  circumference (cm) 79.0 (14.0) 88.3 (11.5) 83.1 (15.5) 104.0 (16.8)
Hip  circumference (cm) 94 (10) 102 (8) 96 (11) 120 (10)
DXA  percentage fat mass 23.8 (11.3) 29.3 (12.5) 29.1 (12.4) 41.8 (8.0)
Hemoglobin (g/l) 136 (13) 138 (14) 135 (15) 136 (16)
White Cell Count *109/l 5.1 (0.7) 5.3 (1.1) 4.8 (1.0) 6.7 (1.0)
Platelets *109/l 189 (25) 225 (52) 197 (30) 165 (82)
Creatinine (mol/l) 70.5 (11.8) 67.3 (11.0) 64.0 (8.9) 70.9 (10.4)
ALT  (IU/l) 32.5 (23.8) 36.4 (25.9) 33.6 (27.6) 46.0 (23.3)
TSH  (U/l) 2.0 (0.8) 2.1 (0.6) 2.0 (0.9) 1.9 (1.0)
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mHbA1c (mmol/mol) 36.0 (4.2) 36.9 (3
a Only 8 of these participants had blood taken and a DXA scan.
esponses is likely to be inadequate to cause clinically beneﬁcial
ffects.
This study used a double-blind, randomised, placebo-controlled,
ross-over design to reduce bias and the effects of inter-individual
ariation. The encapsulated glutamine was tested in healthy indi-
iduals and in patients with type 2 diabetes. The capsules were
esigned to release their contents around 20 min  after exposure to
n alkaline medium, corresponding broadly to the upper-to-mid
leum. Gastrointestinal transit has not been measured and is likely
o vary between individuals, but the capsules were all taken in the
asting state in order to minimize variation in transit time through
he stomach. It is possible that not all capsules left the stomach
t the same time, which might result in a different proﬁle of glu-
amine exposure along the gastrointestinal tract and may  in part
xplain inter-individual differences in response. Due to inter and
ntra-individual variations in gastrointestinal motility, gastric and
ig. 1. Results of the dose ranging study. 4 blinded healthy volunteers attended on 3–4 o
urther study were 3.6 g and 6.0 g in comparison to placebo. Capsules were administere
ean  ± SEM.36.4 (3.6) 57.6 (17.6)
intestinal secretion volumes and capsule opening proﬁles, it is not
possible to know what concentration of glutamine was  reached in
the intestinal lumen. These factors might explain why  the small
GLP-1 responses to capsule ingestion observed in some subjects
were not apparent in others. Theoretically, the dissolution of ten
capsules simultaneously could trigger a sharp but short-lived GLP-
1 response while more gradual dissolution of the capsules may  give
a more gradual GLP-1 release proﬁle. It is likely, however, that the
dose of glutamine was the limiting factor in this experiment. As ten
capsules were required to give a dose of 6 g Glutamine, further dose
increases were not considered feasible within this study design.
The study was  powered according to published data and had
90% power to detect an average difference in GLP-1 of 6.0 pmol/l
(20 pg/ml). However, as the difference in peak GLP-1 seen in the
fasting state during this study was  much lower than this, our study
was not powered to detect such small effect sizes. It also remains
ccasions for administration of increasing doses of glutamine. The doses chosen for
d at time 0, immediately after baseline blood samples were taken. Data represent
42 C.L. Meek et al. / Peptides 77 (2016) 38–46
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dig. 2. Effect of encapsulated glutamine upon concentrations of total GLP-1, insul
ubjects. Capsules were administered at time 0, immediately after baseline blood sa
lutamine or 6.0 g Glutamine in a randomised, blinded, cross-over design. Data rep
nclear what levels of GLP-1 might be required to provoke a mean-
ngful change in clinical endpoints such as glucose tolerance and
eight reduction. In this study, in the fasting state, GLP-1 con-
entrations peaked at ∼10 pg/ml, well below the concentrations
xpected following even a small meal [12]. Indeed, GLP-1 concen-
rations rose much higher to 20–35 pg/ml after the OGTT. Bariatric
urgery has been associated with postprandial total GLP-1 concen-
rations of 100–160 pmol/l (330–520 pg/ml) [13].
Glutamine is known to be associated with increased GLP-1
ecretion and beneﬁcial metabolic effects both in healthy volun-
eers and in patients with type 2 diabetes. Glutamine is known to
levate cAMP and cytosolic calcium in ileal L-cells and is likely to
ind to the calcium sensing receptor (CASR) [14] and the sodium-
ependent transporters such as SLC38A2 and SLC6A19 [6]. L-cells glucose, and subjective measurements of hunger, fullness and nausea in fasting
 were taken. 10 participants attended on 3 occasions and took either placebo, 3.6 g
t mean + SEM.
also express a range of alternative G-protein coupled receptors,
which might be targetable by dietary nutrients or high afﬁnity
ligands [15]. As the EC50 for glutamine-triggered GLP-1 secretion
in vitro was  0.2 mM [6], we speculate that the dose of glutamine
delivered in the capsules was  too low to activate L-cells along a
large length of the small intestine. Previous work by Greenﬁeld
and colleagues has shown that 30 g of oral glutamine in 300 ml
water can stimulate increases in GLP-1 and insulin in healthy and
obese volunteers and patients with type 2 diabetes [7] with mean
peak GLP-1 concentrations of around 22 pmol/l (72 pg/ml) in lean
healthy volunteers. This has led to the hypotheses that glutamine
could be developed therapeutically in patients with impaired glu-
cose tolerance or diabetes [7]. However, the mode of delivery in that
study was challenging as 30 g of glutamine is incompletely soluble
C.L. Meek et al. / Peptides 77 (2016) 38–46 43
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Fig. 3. Effect of encapsulated glutamine upon concentrations of total GLP-1, insulin and glucose, and subjective measurements of hunger, fullness and nausea in healthy
s edia
a nd too
d
i
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w
i
eubjects before and after an oral glucose tolerance test (OGTT) which was  given imm
fter  baseline blood samples were taken. 10 participants attended on 3 occasions a
esign. Data represent mean + SEM.
n 300 ml  water and a ‘swish and swallow’ approach was  required
7,16]. Furthermore, 30 g Glutamine has a calorie content of around
20 kcal and providing additional calories to patients with obe-
ity or type 2 diabetes may  exacerbate glucose tolerance through
eight gain. The aim of the current approach was to identify if
ncreases in gut hormone concentrations and beneﬁcial metabolic
ffects could be harnessed using low doses of glutamine using antely after the 90 min sampling. Capsules were administered at time 0, immediately
k placebo, 3.6 g Glutamine or 6.0 g Glutamine in a randomised, blinded, cross-over
alternative delivery method which aimed to maximize the expo-
sure of glutamine to lower intestinal L-cells. This approach was  not,
however, associated with an increase in circulating GLP-1 concen-
trations comparable to the magnitude of effects seen in Greenﬁeld’s
study. Glucose concentrations were also not affected by glutamine
ingestion in this study, a ﬁnding which is consistent with Green-
ﬁeld’s work [7]. Chang and colleagues tested an alternative method
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17]. They found relatively small increases in GLP-1 (in healthy vol-
nteers and patients with T2DM) and insulin (T2DM only) although
heir participants demonstrated higher baseline total GLP-1 con-en immediately after the 90 min sampling. Capsules were administered at time 0,
ons and took either placebo or 6.0 g Glutamine in a randomised, blinded, cross-overcentrations than those seen in this study, possibly due to the
different analytical methods used for GLP-1 analysis. Their ﬁnding
of low GLP-1 responses to the 7.5 g Glutamine infusion is consistent
with our results, and together both reports suggest that the dose
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f glutamine is limiting, even when administered directly into the
mall intestine.
One unexpected ﬁnding in our study was the increase in meal
ize which occurred following ingestion of glutamine in compari-
on to placebo. As GLP-1 is generally considered to be anorexigenic,
nd 6.0 g glutamine has a caloric value of around 30 kcal, an associ-
tion between glutamine and reduced meal size might have been
xpected rather than the converse. Although blood tests were not
aken during the meal test, participants who received the 6.0 g
lutamine dose prior to an OGTT had slightly higher circulating
oncentrations of GLP-1 and insulin prior to the start of the OGTT
ompared to individuals who received placebo (Fig. 3). As insulin
s considered to be orexigenic [18], it is possible that the increased
nsulin may  explain the increased meal size consumed by partici-
ants. It is possible, however, that other gut hormones or targets of
lutamine might play a role.
No signiﬁcant difference between concentrations of GLP-1,
nsulin or glucose after consumption of the glutamine capsules in
omparison to placebo were found in subjects with type 2 dia-
etes. In patients with diabetes, responses may  be complicated by
ltered background GLP-1 secretory patterns [19,20], gastric emp-
ying [21], or intestinal responsiveness to amino acids in patients
aking metformin [22].In conclusion, orally-administered glutamine capsules did not
rovoke a consistent increase in GLP-1 or insulin in human volun-
eers and was not associated with beneﬁcial effects upon glucoseolunteers ate signiﬁcantly more following ingestion of the 6.0 g Glutamine capsules
 the ad libitum meal. Data are presented as mean ± SEM. The symbol ** denotes
ine dose with placebo.
tolerance or meal size. We  speculate that the low dose of glu-
tamine that could be administered in capsular form was  limiting
in this study, and suggest that the success of future capsule-based
approaches to trigger GLP-1 release will be dependent, at least in
part, on the choice of higher afﬁnity ligands to receptors localised on
L-cells. Further work is needed to identify if other nutritional prod-
ucts could function as more potent agonists to promote endogenous
GLP-1 secretion and harness its clinical beneﬁts.
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